Mammalian polycistronic expression systems for direct translation from RNA and cargo secretion.
Engineered translation initiation sites (eTIS) in polycistronic mRNA allow for precise control of protein stoichiometric ratios and reduced cellular impact, addressing limitations in current protein expression technologies.
JP2026517803APending Publication Date: 2026-06-02CALIFORNIA INST OF TECH
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- CALIFORNIA INST OF TECH
- Filing Date
- 2024-05-02
- Publication Date
- 2026-06-02
Smart Images

Figure 2026517803000001_ABST
Abstract
Disclosed herein are methods, compositions, and kits that enable the expression of multiple payload proteins from a single mRNA configured to achieve a predetermined stoichiometric ratio of a first-unit payload protein and a second-unit payload protein in a cell or cell-like environment. In some embodiments, nucleic acid compositions are provided that include a polynucleotide comprising a first nucleic acid unit (encoding one or more first-unit payload proteins) and a second nucleic acid unit (encoding one or more second-unit payload proteins). Each of the first and second nucleic acid units may include an engineered translation initiation site (eTIS) comprising a tunable element consisting of three nucleotides immediately upstream of the start codon. In some embodiments, the nucleic acid composition comprises at least one modified nucleotide and / or at least one nucleotide analog or nucleotide derivative. In some embodiments, the polynucleotide comprises a disclosed eTIS combination.
Need to check novelty before this filing date? Find Prior Art